Literature DB >> 7902655

Human trypanosomiasis in the Ivory Coast: therapy and problems.

F Doua1, F B Yapo.   

Abstract

Human African trypanosomiasis (sleeping sickness) caused by Trypanosoma gambiense is recrudescing alarmingly in the Ivory Coast. Between 1987 and 1992, 980 new cases were registered. In the Bouafle District alone, 214 new cases were diagnosed in 1992, with a prevalence reaching 7% in some villages. This situation is a consequence of the neglect of control activities over the last five years. The problems linked with treatment of sleeping sickness in 626 patients, using three drugs, are described. The side-effects vary in severity according to the drug used. Out of 350 patients treated with melarsoprol (ARSOBAL), 4% developed encephalopathy, 5.7% died during treatment, 2% of encephalopathy. Relapses were noted in 3.7% of patients between 3 and 20 months after treatment. Among 150 patients treated with pentamidine, one case of diabetes mellitus was observed. The patient died of this complication 24 months after treatment. 2% relapses or reinfections were registered after pentamidine treatment. The most frequently encountered side-effects during intravenous plus oral treatment with DFMO were diarrhoea (64.4%) and anemia (35.5%). This drug was just as effective and better tolerated when treatment was limited to 14 days and administered intravenously only.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902655     DOI: 10.1016/0001-706x(93)90090-x

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  8 in total

1.  In vitro and in vivo activities of trybizine hydrochloride against various pathogenic trypanosome species.

Authors:  R Kaminsky; R Brun
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

2.  Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine.

Authors:  Michael Zhuo Wang; Judy Qiju Wu; Arlene S Bridges; Darryl C Zeldin; Sally Kornbluth; Richard R Tidwell; James Edwin Hall; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2007-08-20       Impact factor: 3.922

Review 3.  Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.

Authors:  M P Barrett; D W Boykin; R Brun; R R Tidwell
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

4.  Cost-effectiveness of algorithms for confirmation test of human African trypanosomiasis.

Authors:  Pascal Lutumba; Filip Meheus; Jo Robays; Constantin Miaka; Victor Kande; Philippe Büscher; Bruno Dujardin; Marleen Boelaert
Journal:  Emerg Infect Dis       Date:  2007-10       Impact factor: 6.883

5.  Application of Hantzsch reaction for sensitive determination of eflornithine in cream, plasma and urine samples.

Authors:  Albandary Almahri; Mohamed A Abdel-Lateef
Journal:  R Soc Open Sci       Date:  2021-05-12       Impact factor: 2.963

6.  Effect of crude extracts of Moringa stenopetala and Artemisia absinthium on parasitaemia of mice infected with Trypanosoma congolense.

Authors:  Tsegabirhan Kifleyohannes; Getachew Terefe; Yacob H Tolossa; Mirutse Giday; Nigatu Kebede
Journal:  BMC Res Notes       Date:  2014-06-24

7.  Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies.

Authors:  Christian Burri; Patrick D Yeramian; James L Allen; Ada Merolle; Kazadi Kyanza Serge; Alain Mpanya; Pascal Lutumba; Victor Kande Betu Ku Mesu; Constantin Miaka Mia Bilenge; Jean-Pierre Fina Lubaki; Alfred Mpoo Mpoto; Mark Thompson; Blaise Fungula Munungu; Francisco Manuel; Théophilo Josenando; Sonja C Bernhard; Carol A Olson; Johannes Blum; Richard R Tidwell; Gabriele Pohlig
Journal:  PLoS Negl Trop Dis       Date:  2016-02-16

Review 8.  Salivarian Trypanosomosis: A Review of Parasites Involved, Their Global Distribution and Their Interaction With the Innate and Adaptive Mammalian Host Immune System.

Authors:  Magdalena Radwanska; Nick Vereecke; Violette Deleeuw; Joar Pinto; Stefan Magez
Journal:  Front Immunol       Date:  2018-10-02       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.